FDA Issues Guidance on Expedited Programs for Serious Conditions - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

FDA Issues Guidance on Expedited Programs for Serious Conditions

FDA has finalized guidance on expedited programs for drugs and biologics to treat serious conditions.  The guidance, released May 29, 2014, details four programs that the agency has designed to facilitate and expedite development and review of new drugs for the treatment of life-threatening conditions. FDA states that the guidance provides information on the four programs, presents criteria for determining if a drug is a candidate for the programs, and is “intended to help ensure that therapies for serious conditions are approved and available to patients as soon as it can be concluded that the therapies’ benefits justify the risks.”

The four programs are Fast-Track Designation, Breakthrough Therapy Designation, Accelerated Approval, and Priority Review Designation.

  • Fast-Track Designation provides frequent discussions about a drug’s development program with FDA to ensure the collection of appropriate data to support approval.
  • Accelerated Approval bases approval on an agreed surrogate marker instead of a clinical endpoint.
  • Priority Review Designation reduces the drug application review time from 10 months to 6 months.
  • Breakthrough Therapy Designation provides fast-track designation as well as FDA staff involvement in the drug development and review process.

In an FDA Voice blog post, Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, details the programs and says that while progress has been made to ensure critical therapies reach patients, “many scientific discoveries still need to be translated into treatments, while patients are urgently waiting for new life-saving therapies.”

According to Woodcock, these expedited drug approval programs have impacted new drug approvals and were used to expedite novel drugs in 2013 with review times as short as 4.5 months. The Breakthrough Therapy Designation has resulted in 48 out of 186 designation requests being granted as of May 5, 2014. And, Woodcock states that 80 new products have been approved through the Accelerated Approval pathway since 1992, resulting in innovative cancer and HIV treatments.

“The Food and Drug Administration (FDA) is committed to doing our part to help bridge this gap. In this context, we have been actively scrutinizing, strengthening and streamlining our regulatory processes at various steps along the path from drug discovery to delivery—including the clinical development phase, the longest and most expensive period of drug development. As part of this effort, we have developed and successfully used a number of flexible and innovative approaches to expedite the development and review of drugs—to the benefit of millions of American patients,” says Woodcock in the blog post.

Source: FDA.gov


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here